Vir Biotechnology, Inc. filed 4 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-24. Between them they name 2 people, with 1 appointment and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Brent Sabatini, Chief Accounting Officer, effective 2026-08-03
Additionally, on July 23, 2026, the Board of Directors of Vir Bio appointed Brent Sabatini, CPA, MBA, Senior Vice President and Chief Accounting Officer of Vir Bio, as interim "principal financial officer" of Vir Bio, effective August 3, 2026.
Reported
On June 9, 2026, the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board from seven to eight members and the appointment of Timothy Coughlin, CPA, to fill the newly created vacancy and serve on the Board as a Class III director until the Company's 2028 annual meeting of stockholders, as well as the appointment of Mr. Coughlin as Chair of the Audit Committee of the Board, in each case effective immediately.
Departing: Saira Ramasastry, Director, effective 2026-05-26
On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company's Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.
Reported
On April 7, 2026, Mark Eisner, MD, MPH, Executive Vice President and Chief Medical Officer of Vir Biotechnology, Inc. (the Company), informed the Company that he will be stepping down from his role, effective April 24, 2026.
Find people with the same kind of experience as the Chief Accounting Officer at Vir Biotechnology, Inc., with the record behind each one.
Find candidates like Chief Accounting Officer at Vir Biotechnology, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Vir Biotechnology, Inc. is in the news or changes leadership.
Get an alert when Vir Biotechnology, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Vir Biotechnology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.